The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.

A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 ...

A new experimental vaccine developed by researchers at MIT and Caltech could offer protection against emerging variants of SARS-CoV-2, as well as related coronaviruses, known as sarbecoviruses, that ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

The University of Queensland's BASE facility – within the Australian Institute for Bioengineering and Nanotechnology (AIBN) – and Brisbane-based biotechnology company Vaxxas have been announced as ...

Legislation that would block hospitals from transfusing blood containing COVID-19 antibodies or “synthetic mRNA” could have ...

The president announced a major AI investment project, which Oracle Chairman Larry Ellison said could be used to cure cancer.